{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:35:02Z","timestamp":1787070902632,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Approximately 50% of autosomal dominant polycystic kidney disease (ADPKD) patients have gross hematuria, but few cases of bladder cancer complications are known. We report a case of a 49-year-old female ADPKD patient with bladder cancer, who was presented to our hospital 4 months after the onset of gross hematuria. A computed tomography (CT) scan showed a bladder mass, enlarged pelvic and left inguinal lymph nodes, multiple liver cysts, and a polycystic kidney. Based on family history, CT scan results, and lymph node biopsy, we diagnosed the patient with uroplakin III-negative bladder cancer with squamous metaplasia and ADPKD. The patient was treated with systemic chemotherapy but died 2 months after the definitive diagnosis. The delayed diagnosis was disastrous, and malignancy should be considered in the differential diagnosis when symptoms suggestive of malignancy such as hematuria appear. Particularly, uroplakin III-negative advanced bladder cancer has a poor prognosis and requires early diagnosis and treatment.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_1310_22","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T04:21:39Z","timestamp":1664857299000},"page":"S925-S927","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Delayed diagnosis of bladder cancer in a patient with autosomal dominant polycystic kidney disease"],"prefix":"10.4103","volume":"19","author":[{"given":"Hirotaka","family":"Suto","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan"},{"name":"Department of Medical Oncology\/Hematology, Kakogawa Central City Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Inui","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology\/Hematology, Kakogawa Central City Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology\/Hematology, Kakogawa Central City Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology\/Hematology, Kakogawa Central City Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice. Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N Engl J Med"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/TCRM.S1617","article-title":"Developments in the management of autosomal dominant polycystic kidney disease","volume":"4","author":"Masoumi","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"Suppl 1","key":"R4-20241021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: Epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrneph.2015.46","article-title":"The hallmarks of cancer: Relevance to the pathogenesis of polycystic kidney disease","volume":"11","author":"Seeger-Nukpezah","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000351049","article-title":"Autosomal dominant polycystic kidney disease: Prevalence of renal neoplasias in surgical kidney specimens","volume":"123","author":"Jilg","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0272-6386(85)80004-4","article-title":"Autosomal dominant polycystic kidney disease: Presentation, complications, and prognosis","volume":"5","author":"Delaney","year":"1985","journal-title":"Am J Kidney Dis"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/bmj.323.7309.386","article-title":"Lesson of the week: Causes of haematuria in adult polycystic kidney disease","volume":"323","author":"Dedi","year":"2001","journal-title":"BMJ"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (Danube): A randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.humpath.2007.04.003","article-title":"Persistent uroplakin expression in advanced urothelial carcinomas: Implications in urothelial tumor progression and clinical outcome","volume":"38","author":"Huang","year":"2007","journal-title":"Hum Pathol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1310_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:38Z","timestamp":1787067518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1310_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":10,"journal-issue":{"issue":"Suppl 2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1310_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"assertion":[{"value":"2022-06-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}